Acne Vulgaris – Epidemiology Forecast to 2026

2018-03-01
Price :
Published : Mar-2018
No. of Pages : 37

Acne Vulgaris – Epidemiology Forecast to 2026

Summary

Acne vulgaris (acne) is a chronic inflammatory skin disease that presents as open or closed comedones and inflammatory lesions. Comedones include blackheads and whiteheads, while inflammatory lesions include papules, pustules, or cysts. Acne is a common skin disease that predominantly affects adolescents and young adults, but can also persist into adulthood. Mortality is not associated with acne, although major physical and psychological characteristics may develop, such as acne scarring, poor self-esteem, depression, and anxiety. The distribution of acne in the population is influenced by genetic background and dietary habits.

For age- and sex-specific total prevalent cases, GlobalData epidemiologists utilized country-specific data from peer-reviewed journal articles, and for age-and sex-specific diagnosed prevalent cases and diagnosed prevalent cases by severity, GlobalData epidemiologists utilized a combination of primary research and data obtained from peer-reviewed journal articles. GlobalData epidemiologists forecast that the total prevalent cases of acne vulgaris in the 7MM will decrease by an Annual Growth Rate (AGR) of negative 0.13% per year over the next 10 years, from 157,919,985 cases in 2016 to 155,935,706 cases in 2026. GlobalData epidemiologists forecast that the diagnosed prevalent cases of acne vulgaris in the 7MM will decrease by an AGR of negative 0.13% per year over the next 10 years, from 78,960,002 cases in 2016 to 77,967,862 cases in 2026. In the 7MM, the US had the highest number of diagnosed prevalent cases with 32,308,734 in 2016, while Spain had the lowest number of diagnosed prevalent cases with 5,766,457 in 2016.

Scope

– The Acne Vulgaris report provides an overview of the risk factors and global trends for acne vulgaris in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
– It includes a 10-year epidemiological forecast for total and diagnosed prevalent cases of acne vulgaris segmented by sex and age (7-9 years, 10-17 years, and 18-60 years). Diagnosed prevalent cases of acne vulgaris are further segmented by severity (mild, moderate, severe) in both children and adolescents (7-17 years) and adults (18-60 years).
– The acne vulgaris epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Acne Vulgaris Epidemiology report will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global acne vulgaris market.
– Quantify patient populations in the global acne vulgaris market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for acne vulgaris therapeutics in each of the markets covered.
– Understand magnitude of acne vulgaris population by disease severity.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – New Zealand

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - New Zealand Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - New Zealand". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in New Zealand. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of New Zealand. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, a......
$1995

Partnerships, Licensing, Investments and M&A Deals and Trends for 2017 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for 2017 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for 2017 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2017. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on th......
$3500

Osteoporosis: Epidemiology Forecast to 2027

Osteoporosis: Epidemiology Forecast to 2027 Summary Osteoporosis is a disease in which the density and quality of bone are reduced over time. In a normal process known as remodeling, some of a person's bone cells dissolve (resorption) and new bone cells grow back (formation). The bones become so weak and brittle that a fall or even mild stresses such as bending over or coughing can cause a fracture. To forecast the total prevalent cases and diagnosed prevalent cases of osteoporosis and osteopenia in the 7MM, GlobalData epidemiologists selected nationally representative, population-based studies that provided these epidemiological data in the 7MM. GlobalData epidemiologists obtained data for the total prevalent cases of osteoporosis secondary to glucocorticoid use from primary market res......
$3995

PharmSource – CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance – 2018 Edition

PharmSource - CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance - 2018 Edition Summary This report is the 8th edition of our long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance. CMO Scorecard is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs. Reasons to buy This 43-page report gives important, expert insight you won't find in any other source. 28 tables and figures throughout the report illustrate major points and trends. This report is required reading for - - CMO executives who must have deep understanding of the injectables marketplace to make strategic planning and investment decisions. - Sourcing and procurement executives who must understand crucial componen......
$4995

Partnerships, Licensing, Investments and M&A Deals and Trends for February 2018 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for February 2018 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for February 2018 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in February 2018. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report......
$1000

Transdermal Drug Delivery – Medical Devices Pipeline Assessment, 2018

Transdermal Drug Delivery - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's Medical Devices sector report, "Transdermal Drug Delivery - Medical Devices Pipeline Assessment, 2018" provides an overview of Transdermal Drug Delivery currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Transdermal Drug Delivery pipeline products. This report is prepared using data sourced from in-house databases, secondary......
$4000

Auto-Immune Diseases Diagnostic Tests – Medical Devices Pipeline Assessment, 2018

Auto-Immune Diseases Diagnostic Tests - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's Medical Devices sector report, "Auto-Immune Diseases Diagnostic Tests - Medical Devices Pipeline Assessment, 2018" provides an overview of Auto-Immune Diseases Diagnostic Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Auto-Immune Diseases Diagnostic Tests pipeline products. This report is prepared using......
$4000

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Belgium

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Belgium Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Belgium". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Belgium. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Belgium. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house anal......
$1995

Neurofibromatoses Global Clinical Trials Review, H1, 2018

Neurofibromatoses Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Neurofibromatoses Global Clinical Trials Review, H1, 2018" provides an overview of Neurofibromatoses clinical trials scenario. This report provides top line data relating to the clinical trials on Neurofibromatoses. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials da......
$2500

Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2018

Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2018" provides an overview of Non Alcoholic Fatty Liver Disease (NAFLD) clinical trials scenario. This report provides top line data relating to the clinical trials on Non Alcoholic Fatty Liver Disease (NAFLD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial ......
$2500